Suzhou Transcenta Therapeutics Co., Ltd.
8 clinical trials · Sponsor
◉ Watch Suzhou Transcenta Therapeutics Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors (NCT05731271) | Suzhou Transcenta Therapeutics Co., Ltd. | 2023-02-08 |
| Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors (NCT04958434) | Suzhou Transcenta Therapeutics Co., Ltd. | 2021-06-11 |
| A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors (NCT04495296) | Suzhou Transcenta Therapeutics Co., Ltd. | 2020-08-13 |
| A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (NCT04396821) | Suzhou Transcenta Therapeutics Co., Ltd. | 2020-05-28 |
| A Study of MSB0254 Injection in Advanced Solid Tumors (NCT04381325) | Suzhou Transcenta Therapeutics Co., Ltd. | 2020-04-01 |
| A Study of MSB2311 in Advanced Solid Tumors (NCT04272944) | Suzhou Transcenta Therapeutics Co., Ltd. | 2018-08-13 |
| A Phase I Study of MSB2311 in Advanced Solid Tumors (NCT03463473) | Suzhou Transcenta Therapeutics Co., Ltd. | 2018-04-12 |
Track Suzhou Transcenta Therapeutics Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.